Börse:

CELLECTAR NEW22 DL-00001

[WKN: A3DQSD | ISIN: US15117F8077]

0,260€ 1,56%

Echtzeit-Aktienkurs CELLECTAR NEW22 DL-00001

Bid: Ask:

Nachrichten zur CELLECTAR NEW22 DL-00001 Aktie

» Nachrichtenticker öffnen

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com

Cellectar Biosciences stock soars on FDA breakthrough designation…

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy…

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

…

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

…

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

…

Earnings call: Cellectar Biosciences outlines robust WM market strategy By Investing.com

Earnings call: Cellectar Biosciences outlines robust WM market strategy…

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

…

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical…

‹
1
›